| | Country | Ethnicity | Case (Age, N) | Control (Age, N) | Control type | Target | Methylation | Specimen | Assay methods | Cutoff | Sensitivity | Specificity |
| | China | Asian | N/A, 96 | N/A, 112 | Benign disease | CfDNA | No | Plasma | qPCR (quantitative) | 0.864 | 73.20% | 72.70% | | China | Asian | N/A, 96 | N/A, 112 | Benign disease | CfDNA | No | Plasma | qPCR (quantitative) | 0.91 | 81.70% | 78.80% | | American | American | 65.5, 89 | 62.9, 163 | Benign disease | GSTP1 | No | Serum | qPCR (quantitative) | 180 ng/ml | 44.90% | 71.80% | | American | American | 65.5, 85 | 63.1, 156 | Benign disease | CfDNA | No | Serum | qPCR (quantitative) | 180 ng/ml | 94.10% | 21.80% | | American | American | 65.5, 85 | 63.1, 156 | Benign disease | CfDNA | No | Serum | Pico green | 53.1 ng/ml | 94.10% | 15.40% | | American | American | 65.5, 85 | 63.1, 156 | Benign disease | CfDNA | No | Serum | Uv absorbance | N/A | 94.10% | 11.50% | | Brazil | American | 66.81, 133 | 66.40, 33 | Benign disease | CfDNA | No | Plasma | Pico green dsDNA quantification reagent kit | 140 ng/ml | 66.20% | 87.90% | | American | American | 64.9, 34 | 64.5, 48 | Benign disease | GADD45a | Yes | Serum | Ms-SNuPE | 89.6 | 38.20% | 97.90% | | American | American | 64.9, 34 | 64.5, 48 | Benign disease | CfDNA | No | Serum | qPCR (quantitative) | 188 | 50.00% | 89.58% | | Italy | European | N/A, 29 | N/A, 25 | Benign disease | CfDNA | No | Urine Supernatant | qPCR (quantitative) | 0.04 ng/ul | 79.00% | 84.00% | | Italy | European | N/A, 55 | N/A, 55 | Benign disease | CfDNA | No | Urine Supernatant | qPCR (quantitative) | 0.04 ng/ul | 58.00% | 47.00% | | China | Asian | N/A, 98 | N/A, 47 | Benign disease | CDH13promoter | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | N/A | 44.90% | 100.00% | | Japan | Asian | 72.2, 76 | 69.4, 20 | Benign disease | Hypermethylation APC | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | 0.002 | 15.00% | 100.00% | | Japan | Asian | 72.2, 76 | 69.4, 20 | Benign disease | Hypermethylation GSTP1 | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | 0.147 | 29.00% | 100.00% | | Japan | Asian | 72.2, 76 | 69.4, 20 | Benign disease | Hypermethylation MDR1 | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | 0.037 | 46.00% | 100.00% | | Japan | Asian | 72.2, 76 | 69.4, 20 | Benign disease | Hypermethylation RASSF1 | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | 0.119 | 24.00% | 100.00% | | Japan | Asian | 72.2, 76 | 69.4, 20 | Benign disease | Hypermethylation PTGS2 | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | 0.091 | 12.00% | 100.00% | | Romania | European | 68.0, 91 | 64.0, 94 | Benign disease | RARβ2 | Yes | Serum | Methylation-specific polymerase chain reaction (MSP) | N/A | 98.00% | 89.00% | | Romania | European | 64.0, 31 | 68.0, 44 | Benign disease | GSTP1 | Yes | plasma | methylation-specific polymerase chain reaction (MSP) | N/A | 87.10% | 93.18% | | American | American | 59.0, 84 | N/A, 30 | AC | MCAM | Yes | Serum | Pyrosequencing | N/A | 66.00% | 73.00% | | American | American | 59.0, 84 | N/A, 30 | AC | MCAM/ERα/Erβ | Yes | Serum | Pyrosequencing | N/A | 75.00% | 70.00% | | Denmark | European | N/A, 27 | N/A, 10 | BPH | CCDC181/ST6GALNAC3/HAPLN3 | Yes | Serum | qMSP | N/A | 67.00% | 100.00% | | Denmark | European | N/A, 27 | N/A, 10 | BPH | ZNF660 | Yes | Serum | ddMSP | N/A | 22.00% | 100.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | FOXA1/RARβ2/RASSF1A/GSTP1 | Yes | Plasma | Multiplex qMSP | N/A | 72.00% | 72.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | FOXA1/RARβ2/RASSF1A) | Yes | Plasma | Multiplex qMSP | N/A | 64.00% | 70.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | FOXA1 | Yes | Plasma | Multiplex qMSP | N/A | 61.00% | 77.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | GSTP1 | Yes | Plasma | Multiplex qMSP | N/A | 15.00% | 98.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | HOXD3 | Yes | Plasma | Multiple qMSP | N/A | 80.00% | 43.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | RARβ2 | Yes | Plasma | Multiplex qMSP | N/A | 22.00% | 96.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | RASSF1A | Yes | Plasma | Multiplex qMSP | N/A | 13.00% | 96.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | SEP-19 | Yes | Plasma | Multiplex qMSP | N/A | 12.00% | 99.00% | | Portugal | European | 71.0, 121 | 57.0, 136 | AC | SOX17 | Yes | Plasma | Multiplex qMSP | N/A | 29.00% | 93.00% |
|
|
BPH, benign prostatic hyperplasia; AC, asymptomatic control; cfDNA, cell-free DNA; qMSP, quantitative methylation-specific PCR; ddMSP, methylation-specific droplet digital PCR; N/A, not available; N, number.
|
